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Summary Lymph node status is still the single most important prognostic factor in breast cancer. Axillary
surgery remains the only reliable means ofproviding this information. This pilot study evaluates using a highly
specific radiolabelled monoclonal antibody to provide equivalent infornation by a non-invasive technique.
After optimisation of labelling conditions, our first antibody, ICR12 (against the gene product of c-erbB-2)
was evaluated in a mouse model system. Twenty-four hours post i.v. injection the mice were killed and their
organs, blood and tumours harvested for counting. Tumour localisation was four times greater than that into
normal tissues, reaching 20% injected dose per gram of tumour.
Eight patients have had this Tc99m-ICR12. Patient selection was by immunocytochemical staining of fine
needle aspirates from the patient's own breast cancer. After intravenous administration of the immunocon-
jugate, tomographic images were obtained at 24h. These results were compared to the subsequent histo-
pathological examinations. Three patients acted as normal controls, one patient was negative due to inappro-
priate sampling, and two patients had strong membrane staining and provided excellent tumour localisation to
both breast primary and regional node metastases. A further two patients only had moderate antigen
expression on staining and did not localise well.
The good performance of this radiolabelled antibody with patients that strongly stain for the antigen
encourages the development of this system as both a method ofstaging breast cancer and a potential means of
immunotherapy in this subgroup of patients.
Radioimmunolocalisation, the use of radiolabelled mono-
clonal antibodies to localise tumour deposits displaying the
target antigen, has been used in the staging of breast cancer
with varied results (Tjandra et al., 1989a,b; Athanassiou et
al., 1988). Successful localisation of an antibody to the target
antigen relies firstly on there being a high level of antigen
expression by the tumour relative to normal tissues (Wein-
stein et al., 1984; Vaickus & Foon, 1991) and secondly, the
availability of highly specific antibodies which recognise the
target antigen. This tumour specificity is itself an essential
prerequisite to any future development ofimmunotherapeutic
applications (Bradwell et al., 1985; Schlom, 1989). Most
previously reported studies have used a single monoclonal
antibody of moderate specificity for a tumour to investigate
the potential for staging all cases of that cancer type under
investigation (Thompson et al., 1984; Yiu et al., 1991), with-
out making allowance for heterogeneity of antigen expression
either between different tumour deposits or within a tumour
itself. In addition, the level of antigen expression in many
tumours is not signficantly elevated above that found on
normal tissues, thus making successful tumour localisation
unlikely.
We have tried to circumvent these problems of variable
antigen expression by using a panel of monoclonal antibodies
that are highly specific to clearly defined, but not universally
expressed, cell surface antigens. By selecting the antibody for
radioimmunolocalisation studies on the basis of prior im-
munostaining of fine needle aspirates of each tumour we
aimed to identify the best antibody to be used for the inves-
tigation of each individual patient. We present the results
from the first of our antibodies, ICR12 (Styles et al., 1990)
that has been fully evaluated both in vitro, in vivo and in
clinical cases. This antibody, which is a rat IgG2a mono-
clonal, is directed against the extracellular domain of the
185 kDa product of the c-erbB-2 proto-oncogene; a trans-
membrane tyrosine kinase related to the receptor for epidermal
growth factor. Amplification of this gene and overexpression
of the product has been found in some 20% of breast cancers
and overexpression has been found to correlate with poor
prognosis in these patients (Slamon et al., 1987; Gusterson et
al., 1988). The minimal levels of expression of this antigen in
most normal tissues make this a highly tumour specific target
(Perren, 1992). ICR12 was selected from a panel of rat
monoclonal antibodies to p185 (Dean et al., 1992) on the
basis that it binds both to frozen and formalin fixed paraffin
embedded tumour sections that overexpress p185 and it will
localise with high efficiency and stability to p185 expressing
breast and ovarian xenografts in athymic mice (Bakir et al.,
1992).
Methods
Patient selection
Patients were recruited for inclusion into this study from
staging clinics at The Royal Marsden Hospital, Sutton. All
patients had primary breast cancer, were aged between
35-80 years and were recruited prior to surgical management
of the axilla. Written consent was obtained from each patient
following approval of the protocol by The Royal Marsden
Hospital Ethical Committee. The diagnosis of breast cancer
relied on the triple approach of clinical findings, mammo-
graphy and positive fine needle aspiration cytopathology or
core biopsy histopathology.
Immunostaining
Tumour cells obtained by fine needle aspiration were sus-
pended in minimum essential medium with 25 mMolar
HEPES buffer and phenol red. Aliquots of the suspension
were cytocentrifuged using the Shandon cytospin centrifuge
to provide an adequate number of equivalent samples for
both cytopathology and immunocytochemical staining (Fer-
nando et al., 1992a). Immunostaining was by the indirect
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imunoperoxidase technique (Fernando et al., 1992b) (Figure
1) and the results obtained with the cytospin samples were
verified by staining of fixed paraffin embedded tissue ob-
tained from the surgically resected specimen (Fernando et al.,
1992b). Strong staining was defined as dense immunoperox-
idase brown staining of greater than 50% of malignant cell
membranes. Whereas, moderate staining was defined by us as
some evidence of brown staining being present on less than
50% ofmalignant cell membranes within any one high power
microscopic field of view.
Radiolabelling procedure
After consideration ofprevious studies with differing isotopes
and differing labelling methods including chelation methods
of labelling with Tc99m, Technetium-99m was selected as the
radioisotope for use with a reduction method of labelling
because of the short half life, excellent imaging characteristics
and ease of radiolabelling. ICR12 is labelled with Tc99m
using a modification of the Mercaptoethanol reduction me-
thod (Schwarz & Steinstraesser, 1987; Mather & Ellison,
1990). Initial tests showed that the optimal labelling condi-
tions for ICR12 with minimal affect on antibody binding
required a modification of the standard technique. Briefly,
the optimal conditions were achieved by treatment of the
antibody by part reduction with 2-mercaptoethanol (2ME) at
a molar ratio of 500 parts 2ME: 1 part antibody, for 30min
at room temperature. The partially reduced antibody was
separated from excess reductant by passage through a 10 by
1 cm column of Sephadex G25 previously equilibrated with
phosphate buffered saline (pH 7.4) and blocked with human
serum albumin. The partially reduced antibody elution frac-
tion was both identified and quantified by measuring the
optical density of the fractions at 280 nm wavelength against
a saline control. The identified protein containing fraction is
then frozen at - 20°C prior to completion of the labelling
process. The final stage of labelling involves the further
reduction of the partly reduced antibody using a standard
bone scanning kit 'Osteoscan HDP' (Mallinckrodt Medical)
at 100 microlitres from the reconstituted kit, (stannous chloride and disodium oxidronate, one vial reconstituted with
5 ml phosphate buffered saline) per milligram of the reduced
antibody in the presence of 1000 MBq of Tc99m. Further gel filtration removed any non-protein bound Tc99m and the
final labelled antibody preparation was then sterilised by microfiltration using a 0.22 micron low protein loss mem-
brane filter (Millex-GV, Millipore). This technique of pre- paration has been tested for sterility and pyrogenicity by accredited commercial quality control testing laboratories.
Labelling efficiency was checked prior to use ofeach batch of
Figure 1 Membrane staining showing positive immunostaining on cytospin preparation from fine needle aspirate of breast primary.708 S.M. ALLAN et al.
prepared antibody by instant thin layer chromatography.
In the preclinical studies, the effects of differing conditions
of radiolabelling on the immunoreactivity of the antibody
were established using competitive radioimmunoassay techni-
ques (Bakir et al., 1992). ICR12 labelled with Tc99m (decayed)
was compared with unlabelled ICR12 for its capacity to
compete with Iodine-125 labelled ICR12 for binding to the
human ovarian carcinoma cell line SKOV3 cells which over
expresses the target antigen (Bakir et al., 1992) (Figure 2).
Standard competitive radioimmunoassay techniques were
employed with doubling dilutions of each test antibody
against the 1-125-antibody down the cell plate. Further deter-
mination of the effect of labelling on immunoreactivity of the
radiolabelled antibody was performed by immunoprecipita-
tion studies of Tc99m labelled antibody binding to Sepharose
4B beads coated with an excess of the p185 antigen. The
resultant trapping of the active, labelled antibody to the
antigen coated beads was measured in an automated gamma
counter. This method of testing demonstrates the combined
effects of both labelling efficiency and immunoreactivity,
rather than testing each function in isolation.
Biodistribution studies in vivo
Eight athymic mice bearing established bilateral xenografts of
the human breast carcinoma MDA MB-361 tumours were
injected intravenously with 100 micrograms ofTc99m-ICRI2
and then killed at 24 h by CO2 asphyxiation. Radioactivity in
weighed samples of blood, lungs, liver, spleen, kidneys, mus-
cle, skin and tumours was determined in a gamma well
spectrometer and the results expressed in terms of per cent
injected dose per gram of tissue (% ID g-').
Imaging technique
Patients were given 2 mg of ICR12 labelled with 700 MBq of
Tc99m by slow intravenous injection. Axillary and thoracic
regions were imaged at 24 h after injection using a General
Electric Maxi gamma camera with a standard collimator.
Planar acquisition of approximately 200,000 counts was per-
formed initially, followed by 360 degree tomography acquir-
ing in 64 projections for 30 s at each angle. Computerised
reconstruction was then undertaken to provide tomographic
representations in the transaxial, sagittal and coronal planes.
Reconstruction of images was performed using a ramp filter,
and these transaxial reconstructions were analysed further by
computer to show levels of activity in regions of interest thus
quantifying the imaged results.
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Figure 2 Competitive radioimmunoassay of unlabelled ICR12
(control) vs Tc99m labelled ICR12 (decayed) on Skov 3 cell
plates against 1-125 labelled ICR12.
Results
Radiolabelling ofICR12 with Tc99m
Experimentation was carried out initially to determine the
optimum conditions for reduction of the antibody with 2ME.
The conditions were varied in each experiment in terms of
the molar ratios and the results of these experiments com-
pared in terms of labelling efficiency, immunoreactivity and
structural damage to the antibody. The process of labelling
was demonstrated not to damage the structural integrity of
the antibody by SDS-PAGE gel electrophoresis studies and
the function of the antibody was demonstrated to be
unaffected by the process of radiolabelling by competitive
radioimmunoassay against Iodine-125 labelled ICR12 on
SKOV 3 cell plates. The results of these experiments demon-
strated the optimum labelling conditions for ICR12 and these
differed for this rat monoclonal antibody from the originally
reported technique describing murine antibodies. The
modified protocol produced satisfactory labelling with
Tc99m, such that the labelled antibody was indistinguishable
from the Iodine labelled control antibody in terms of
immunoreactivity. Labelling efficiency was checked on each
preparation by instant thin layer chromatography using nor-
mal saline as the solvent carrier and these results were
confirmed in the initial instances by high pressure liquid
chromatography. Labelling efficiency had to exceed 95%
(after purification by gel filtration) for satisfactory labelling
to be accepted and this level of efficiency was demonstrated
to be stable for a duration of 24 h in vitro and in animal
models. Combined immunoreactivity and labelling efficiency
was assessed by competitive immunoprecipitation assay on
antigen linked Sepharose 4B beads and shown to be in the
region of the potential maximum value, which compared
favourably to those results obtained with 124-Iodine labelled
ICR12 (Bakir et al., 1992). This combined test showed that
whilst maintaining very high labelling efficiency levels, the
reduction method of labelling did not produce loss of
immunoreactivity when compared to more established labell-
ing methods.
Biodistribution ofTc99m-ICRJ2 in athymic mice bearing
MDA MB-361 xenografts
To determine the effect of the radiolabelling procedure on the
biodistribution and tumour localisation of ICR12 studies
were undertaken within a nude mouse model system. Eight
athymic mice bearing bilateral subcutaneous human xeno-
graft tumours of MDA MB-361 were injected intravenously
with 100 micrograms of Tc99m labelled ICR12 and killed at
24h. Imaging on a gamma camera was performed at this
point (Figure 3) and various organs and tissues harvested for
counting in an automated gamma well counter. The results
determined as percentage injected dose per gram of tissue for
the various tissues samples at 24 h are shown in Figure 4.
The blood and normal tissue activity levels were comparable
to those found in a similar study using Iodine-124 with the
exception of the level of kidney uptake which may well
represent the renal excretion of the radiolabel, or a small
amount of free Tc99m present in the preparation. After 24 h
Tc99m-ICR12 localised into tumour on average four times
greater than any other normal tissue. Blood levels were half
those in the tumour at 24 h and the mean tumour localisa-
tion was 20.7% of the total injected dose per gram weight of
tumour (range 13.8% to 32.4% ID g-'). These results of
tumour localisation were the highest mean value obtained
with this xenograft test system using ICR12 labelled with
several different radionuclides and labelling methods includ-
ing Tc99m with a chelation labelling technique (Dean et al.,
1992). We concluded that not only were the biological and
immunological properties of ICR12 not detectably altered by
this method of labelling with Tc99m, but that this is an
excellent method of producing radiolabelled antibodies for
clinical use. To ensure that the antibody preparations for
clinical studies remained at such high quality, samples of thec-erbB2 RADIOIMMUNOLOCALISATION 709
Figure 3 Image of nu/nu mouse bearing bilateral flank tumours (MDA MB 361 xenografts) taken at 24 h post injection.
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Figure 4 Mean percentage injected dose Tc99m-ICR12 per gram of tissue at 24 h in mouse model system.
clinical investigation preparations were tested in this animal
model in tandem to clinical studies. This allowed
confirmation of the labelled antibody immunoreactivity in
each clinical trial case, thus acting as a positive control.
Patient studies
To date eight patients have been studied with Tc99m-ICRi2,
(Table I) three of these acted as normal controls since their
tumours did not show over expression ofthe gene product on
their cell membranes in either their fine needle aspirates or
their surgical resection specimen paraffin embedded sections
from the tumour or axillary lymph nodes.
Two patients had marked over expression of the antigen
on pretesting. In the first case (Patient 4) excellent images
were obtained on tomographic reconstruction of both the
primary and nodal tumour deposits. The second case (Patient
5) had even stronger immunostaining on pretesting with
CD
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Table I Clinical results with Tc99M-ICR12
Immuno-
Clinical Antigen Histological localisation
Patient node status expression node status result
I - - +
2 + - + _
3 - + (Only in DCIS)
4 + +++ + ++
5 + +++ + ++
6 + - + _
7 - + (Moderate) - +/-
8 + + (Moderate) + +/-
DCIS = Ductal carcinoma in situ; Moderate = <50% cells
showing some membrane immunostaining.
marked homogeneity of the neoplastic cell staining. Radioim-
munolocalisation images easily identified the tumour deposits
on both planar imaging (Figure 5) as well as the computer
enhanced tomographic reconstructions (Figure 6). The recon-
structed transaxials were then further examined to show
region of interest axes and the highlighted tumour deposits
showed levels of activity at least three times that of back-
ground admixture of blood and normal tissue levels of
activity (Figure 7). The line axes show activity levels through
both breasts along the horizontal axis, while the vertical axis
compares the total body mass and blood background against
the tumour activity level.
One patient selected for inclusion in the study as a
'positive expresser' of the c-erbB-2 p185 on the basis of
staining of the fine needle aspirate failed to localise on
radioimmunoscintigraphy with Tc99m-ICR12 (Patient 3). Im-
munostaining of the surgically resected specimens showed
that whilst there was over expression of the gene product on
surrounding ductal cancer in situ, the infiltrative component
of the tumour which formed the bulk of the tumour mass did
not stain. The tandem mouse study showed that the labelled
antibody behaved as expected. We concluded that this case
represented a problem of sampling by fine needle aspiration
rather than a problem with the monoclonal antibody.
Two further patients had only weak to moderate expres-
sion of the antigen on their breast cancer cell membranes as
shown by pretesting immunostaining. In addition both of
these patients had had three or more months of presurgical
treatment with Tamoxifen as part of a primary medical
treatment programme. Neither of these two patients demon-
strated good localisation to either the breast primary or the
axillary nodes with Tc99m-ICRI2 radioimmunolocalisation.
Whether this was due to the lower degree of antigen expres-
sion being displayed by the target tumour, or whether the
previous hormonal treatment had in some way modified the
immunological target remains to be clarified.
Discussion
Our results from the preclinical evaluation experiments and
the subsequent clinical evaluation provide support for the
hypothesis that the use of a highly specific antibody against a
preselected target will improve the prospects for accurate
localisation of tumour deposits by radioimmunolocalisation.
The assessment of the efficiency of staining of fine needle
aspirates for characterisation of the tumour target has given
good agreement with definitive pathological examination and
immunocytochemical (Fernando et al., 1992b) although one
result (Patient 3) points to the need for careful sampling.
The results of this radioimmunolocalisation study support
our hypothesis that in order to improve on previously
reported results where a single monoclonal antibody is
expected to localise in all cases of a particular tumour type.
We recognised that this is asking too much of any individual
antibody and have therefore selected antibodies to form a
panel from which an antibody is targeted to a specific and
predetermined target antigen. By having a panel of highly
specific antibodies, from which one is chosen on the basis of
testing each individual tumour target antigen expression, the
ability of the chosen antibody to recognise that particular
Figure 5 Planar image from patient five, showing both primary and node uptake.c-erbB2 RADIOIMMUNOLOCALISATION 711
Figure 6 Transaxial, coronal and sagittal reconstruction slices through the axilla, showing uptake in the node metastases in patient
five.
Figure 7 Transaxial reconstruction showing levels of activity along axes lines of interest through the breast primary tumour of
patient five.
individual tumour being tested is therefore established prior
to the study. It is in using this method of preselecting
antibodies for the task in hand that radioimmunolocalisation
will be more likely to provide accurate data for staging
purposes. We do however recognise that the extent of the
antigen expression and any modifying factors such as pre-
treatment should be taken into consideration in this selection
process.712 S.M. ALLAN et al.
The results presented in this paper are the initial results of
the first antibody from our panel of highly specific anti-
bodies, and show the potential of such a directed means of
investigation. The excellent localising properties of ICR12
into tumours that strongly over express c-erbB-2 p 185 and
the absence of uptake of this antibody in antigen negative
tumours and normal breast tissue suggest that it may have a
useful clinical role in staging patients and should be included
as a constituent member of our eventual completed panel of
antibodies for staging breast cancer.
Recent reports (Wright et al., 1992; Gusterson et al., 1992)
suggest that breast cancer patients with tumours that over
express the product of the c-erbB-2 proto-oncogenes have a
poor prognosis because the tumours are more resistant to
chemotherapy or hormonal manipulation. The results of our
initial study with ICR12 reported in this paper suggest that
the good tumour localising properties of this antibody in
those patients that strongly overexpress the target antigen
may form a basis for its use in therapeutic applications in
these patients, for example in antibody directed prodrug
therapy or targeted immunotherapy with either antibody
targeted toxins or antibody delivered radiotherapy. In con-
clusion, not only could ICR12 form part of a panel of
antibodies to stage breast cancer and thereby replace axillary
surgery as a diagnostic procedure in this condition, but also
that the antibody may be of use for delivering and directing
subsequent therapeutic management in those patients that
strongly over express the c-erbB-2 gene product.
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